Mycobacterium bovis Bacille Calmette-Guerin (BCG), the first Federal Drug Adminstration (FDA) approved oncolytic bacteria [166], exerts antitumor activity by stimulating the release of inflammatory mediators CD-4, CD-8 and TNF-α, provoking a localized area of chronic inflammation to enhance immune surveillance and tumor regression [167]. Here, CD8A is linked to neoplasm.